Precision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research.
Loading...
Embargo End Date
ICR Authors
Authors
Dimou, P
Trivedi, S
Liousia, M
D'Souza, RR
Klampatsa, A
Trivedi, S
Liousia, M
D'Souza, RR
Klampatsa, A
Document Type
Journal Article
Date
2022-04-06
Date Accepted
2022-04-01
Abstract
Precision-cut tumor slices (PCTS) have recently emerged as important ex vivo human tumor models, offering the opportunity to study individual patient responses to targeted immunotherapies, including CAR-T cell therapies. In this review, an outline of different human tumor models available in laboratory settings is provided, with a focus on the unique characteristics of PCTS. Standard PCTS generation and maintenance procedures are outlined, followed by an in-depth overview of PCTS utilization in preclinical research aiming to better understand the unique functional characteristics of cytotoxic T cells within human tumors. Furthermore, recent studies using PCTS as an ex vivo model for predicting patient responses to immunotherapies and other targeted therapies against solid tumors are thoroughly presented. Finally, the advantages and limitations of the PCTS models are discussed. PCTS are expected to gain momentum and be fully utilized as a significant tool towards better patient stratification and personalized medicine.
Citation
Antibodies, 2022, 11 (2), pp. 26 -
Source Title
Antibodies
Publisher
MDPI
ISSN
2073-4468
eISSN
2073-4468
2073-4468
2073-4468
Collections
Research Team
Thor Onco Immuno Group